Acalabrutinib plus rituximab for older untreated DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies the combination of acalabrutinib and rituximab in older or frail people with newly diagnosed DLBCL (a type of lymphoma). It aims to see how well this treatment works and how safe it is for people who may not be able to tolerate standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 80 or older, or age 65 to 79 and not able to receive chemoimmunotherapy
- You have DLBCL confirmed by biopsy, and you have not had any prior treatment for DLBCL
- Your lymphoma stage is II, III, or IV
- Your overall health is good enough for study treatment (performance status 0, 1, or 2)
- You have at least one measurable lymphoma spot of at least 10 mm on a CT or MRI scan
- Your kidneys, liver, and bone marrow function are adequate for treatment (based on screening blood tests)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether adding acalabrutinib to intensive chemo (DA-EPOCH-R or R-CHOP) works better for people newly diagnosed with aggressive diffuse large B-cell lymphoma (DLBCL) or related high-grade B-cell lymphomas. It may help shrink cancer and control the disease by targeting lymphoma in two different ways.
This study tests whether adding acalabrutinib to a reduced-strength chemotherapy plan (R-miniCHOP) works better and is safer for older adults with newly diagnosed diffuse large B-cell lymphoma. It may help you get a more effective treatment while using a dosing approach meant for people who may not tolerate full-strength therapy.
This trial studies acalabrutinib given after certain lymphoma treatments (like stem cell transplant or CAR T therapy) to help keep the lymphoma from coming back. It’s for people whose disease has shrunk (partial response) or fully gone away (complete response) after those treatments.
This trial tests a combination of four medications (pomalidomide, rituximab, orelabrutinib, and polatuzumab vedotin) for newly diagnosed, elderly patients with diffuse large B-cell lymphoma (DLBCL) who cannot tolerate standard treatments. It aims to see if this combination is effective and safe for older adults.
This trial tests a combination of two targeted drugs (acalabrutinib and rituximab) for people with mantle cell lymphoma who have not had treatment before. It is designed for older patients or younger patients with a less aggressive form of the disease.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.